MESOBLAST LIMITED

MESO ·Healthcare, Drug Manufacturers - General, Australia
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017 FY2016
Revenue $2.4M $42.5M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development
SG&A Expense
Operating Income $-90.2M $-90.8M
Operating Margin -3,740.3% -213.5%
Interest Expense
Pretax Income $-90.2M $-90.8M
Income Tax Expense $-13.4M $-86.7M
Net Income $-76.8M $-4.1M
Net Margin -3,184.7% -9.7%
EPS (Basic) $-0.19 $-0.01
EPS (Diluted) $-0.19 $-0.01
Shares Outstanding (Basic)
Shares Outstanding (Diluted)
Dividends Per Share
← Newer Page 2 of 2 Older →